Abaloparatide · source year
5 selected, source-linked Abaloparatide records carrying a 2017 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
2 represented types.
5 distinct public records.
Cited chronology
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 27894941 at 2026-07-30T21:22:58.009Z. PubMed recorded a metadata revision date of 2017-12-23 and an Entrez history date of 2016-11-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 28160873 at 2026-07-30T21:25:18.679Z. PubMed recorded a metadata revision date of 2017-05-31 and an Entrez history date of 2017-02-06. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗